Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PKLR | P30613 | 1/20 | 0.53 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.48 |
| ▸ | TUBB | P07437 | 5/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967207 | 0.81 | GAA (0.47) | PKMPKLRGAAKDM4EALDH1A1 | |
| SCHEMBL1967013 | 0.81 | BACE1 (0.49) | APPBACE1JAK2BRD4JAK1 | |
| SCHEMBL1970425 | 0.80 | GAA (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1967089 | 0.79 | GAA (0.62) | PKMPKLRGAAKDM4EALDH1A1 | |
| SCHEMBL1965240 | 0.78 | GAA (0.53) | PKMPKLRGAAKDM4EALDH1A1 | |
| SCHEMBL1970576 | 0.77 | GAA (0.47) | PKMPKLRGAAKDM4EALDH1A1 | |
| SCHEMBL1964935 | 0.76 | GAA (0.51) | PKMPKLRGAAKDM4EALDH1A1 | |
| SCHEMBL1966488 | 0.75 | GAA (0.46) | PKMPKLRGAAKDM4EALDH1A1 | |
| SCHEMBL1964836 | 0.72 | GAA (0.54) | GAAKDM4EALDH1A1MAPTTP53 | |
| SCHEMBL1968357 | 0.71 | GAA (0.51) | PKMPKLRGAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | claimed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | claimed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| EP-2334675-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | TYMP, IMPDH1, DPYD | PKM 3234/4885PKLR 2992/4885TUBB4A 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.